Investor Announcements - 2019


EKF Diagnostics Holdings plc announces its final results for the year ended 31 December 2018.

EKF announces that it will release its preliminary results for the year ended 31 December 2018 on Wednesday 13 March 2019.

EKF Diagnostics announces that its Quo-Test analyser has received US Food and Drug Administration 510(k) clearance for professional use in a clinical laboratory setting.

EKF announces the full launch of the McKesson Consult® Hb analyzer in the US  in February.

EKF Diagnostics provides shareholders with the following update on current trading.